Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Smartphone Application for Automated Measurement of Capillary Refill Time (CRT)

NCT07473869 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-06-01
Last updated
2026-03-16

Condition(s) studied

Capillary Refill TimePeripheral Tissue Perfusion

Study summary

This prospective, monocenter observational study aims to validate a smartphone application (CRTApp) that automatically measures capillary refill time (CRT) from a short video of a standardized finger compression. Sixty adult intensive care unit (ICU) patients will undergo a CRT measurement recorded with a professional Android smartphone. Clinical CRT will be determined from the video by three blinded observers (reference = median of the three measurements). The application will analyze the same video locally to provide an automated CRT measurement. Agreement between automated and clinical reference CRT will be assessed, and predefined subgroup analyses will explore performance across skin tone, ambient lighting, smartphone characteristics, and severity of peripheral hypoperfusion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Adult patients hospitalized in an intensive care unit * Clinical indication for capillary refill time assessment (hemodynamic monitoring, suspected peripheral hypoperfusion, or therapeutic evaluation) * No objection from the patient or legal representative Exclusion Criteria: * Skin lesions at the measurement site * Known severe peripheral vascular disease * Finger amputation * Presence of distinctive skin marks on fingers (tattoos, significant scars, or prominent moles) that may interfere with measurement or increase the risk of patient re-identification

Primary outcome measure(s)

  • Agreement Between Automated and Clinical Capillary Refill Time Measurement — At inclusion (single assessment)
    Agreement between capillary refill time measured by the smartphone application and the clinical reference measurement performed by expert clinicians using the standardized method (10-second glass slide compression). Agreement is assessed using the intraclass correlation coefficient between the automated measurement and the median of three blinded observers.

Trial sites (1)

FacilityCityRegionStatus
CHU Bicêtre Le Kremlin-Bicêtre France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07473869 on ClinicalTrials.gov ↗ ← All trials in France